United Bank Has Boosted Union Pacific (UNP) Position; Last Week Eleven Biotherapeutics (EBIO) Coverage

September 5, 2017 - By Hazel Jackson

Among 2 analysts covering Eleven Biotherapeutics (NASDAQ:EBIO), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Eleven Biotherapeutics had 4 analyst reports since August 15, 2015 according to SRatingsIntel. Leerink Swann downgraded Eleven Biotherapeutics Inc (NASDAQ:EBIO) on Tuesday, January 19 to “Market Perform” rating. The company was maintained on Wednesday, March 16 by Citigroup. The stock of Eleven Biotherapeutics Inc (NASDAQ:EBIO) has “Neutral” rating given on Tuesday, January 19 by Citigroup. The firm has “Outperform” rating given on Saturday, August 15 by Leerink Swann. See Eleven Biotherapeutics Inc (NASDAQ:EBIO) latest ratings:

United Bank Inc increased Union Pacific (UNP) stake by 7.75% reported in 2016Q4 SEC filing. United Bank Inc acquired 2,954 shares as Union Pacific (UNP)’s stock declined 2.52%. The United Bank Inc holds 41,055 shares with $4.26M value, up from 38,101 last quarter. Union Pacific now has $84.42B valuation. The stock increased 0.16% or $0.17 on September 1, reaching $105.47. About shares traded. Union Pacific Corporation (NYSE:UNP) has risen 31.45% since September 5, 2016 and is uptrending. It has outperformed by 14.75% the S&P500.

Since March 10, 2017, it had 0 insider purchases, and 1 insider sale for $106,890 activity. The insider Whited Elizabeth F sold 1,000 shares worth $106,890.

Investors sentiment increased to 0.92 in 2016 Q4. Its up 0.10, from 0.82 in 2016Q3. It increased, as 55 investors sold UNP shares while 509 reduced holdings. 112 funds opened positions while 390 raised stakes. 620.05 million shares or 0.84% less from 625.33 million shares in 2016Q3 were reported. Alpha Windward Ltd Company stated it has 2,328 shares or 0.16% of all its holdings. Copeland Ltd Liability invested in 0.13% or 19,623 shares. Epoch Invest Prtn Incorporated stated it has 57,375 shares or 0.02% of all its holdings. National Bank & Trust Of America De has invested 0.36% in Union Pacific Corporation (NYSE:UNP). Moreover, Advantage has 3.74% invested in Union Pacific Corporation (NYSE:UNP). Logan Management Inc holds 0.02% or 2,400 shares in its portfolio. Invest Management Of Virginia Limited Liability Company reported 13,421 shares stake. Wexford Cap LP invested in 0.36% or 33,924 shares. Mitchell Mcleod Pugh Williams holds 17,530 shares. Security Fincl Bank Of Sioux City Iowa Ia has 1.71% invested in Union Pacific Corporation (NYSE:UNP). Cutter And Brokerage invested 0.76% of its portfolio in Union Pacific Corporation (NYSE:UNP). Nebraska-based Nelson Van Denburg & Campbell Wealth Management Grp Lc has invested 1.07% in Union Pacific Corporation (NYSE:UNP). 2.10 million are owned by Viking Glob L P. 579,126 were reported by Polar Cap Ltd Liability Partnership. Fil Limited stated it has 0.62% in Union Pacific Corporation (NYSE:UNP).

Among 24 analysts covering Union Pacific Corporation (NYSE:UNP), 12 have Buy rating, 1 Sell and 11 Hold. Therefore 50% are positive. Union Pacific Corporation had 67 analyst reports since July 24, 2015 according to SRatingsIntel. On Thursday, January 21 the stock rating was maintained by Cowen & Co with “Outperform”. Cowen & Co maintained the shares of UNP in report on Monday, October 5 with “Outperform” rating. On Thursday, June 16 the stock rating was initiated by Oppenheimer with “Perform”. The firm earned “Buy” rating on Tuesday, March 8 by UBS. RBC Capital Markets maintained it with “Outperform” rating and $105 target in Wednesday, September 2 report. Stifel Nicolaus maintained Union Pacific Corporation (NYSE:UNP) on Friday, August 18 with “Hold” rating. The firm earned “Buy” rating on Monday, January 25 by Argus Research. The stock has “Buy” rating by BMO Capital Markets on Thursday, June 1. The stock of Union Pacific Corporation (NYSE:UNP) has “Equal-Weight” rating given on Monday, April 11 by Barclays Capital. The stock has “Neutral” rating by Buckingham Research on Wednesday, January 18.

Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The company has market cap of $27.42 million. The Firm applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. It has a 5 P/E ratio. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema and uveitis.

Investors sentiment decreased to 1.83 in 2016 Q4. Its down 0.05, from 1.88 in 2016Q3. It turned negative, as 6 investors sold Eleven Biotherapeutics Inc shares while 5 reduced holdings. 5 funds opened positions while 6 raised stakes. 1.14 million shares or 22.20% more from 933,766 shares in 2016Q3 were reported. Moreover, Citigroup has 0% invested in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Blackrock Institutional Na invested 0% of its portfolio in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Northern stated it has 0% in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Susquehanna Group Llp reported 15,586 shares stake. Oxford Asset Mgmt has invested 0.02% of its portfolio in Eleven Biotherapeutics Inc (NASDAQ:EBIO). 100 were accumulated by Reilly Fincl Advisors Ltd Llc. Barclays Public Ltd Limited Liability Company invested in 13 shares or 0% of the stock. Airain holds 25,160 shares. Credit Suisse Ag owns 0% invested in Eleven Biotherapeutics Inc (NASDAQ:EBIO) for 14,860 shares. Fiduciary holds 0% or 10,000 shares in its portfolio. Geode Mngmt Ltd Limited Liability Company has invested 0% in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Royal National Bank & Trust Of Canada owns 0% invested in Eleven Biotherapeutics Inc (NASDAQ:EBIO) for 500 shares. Blackrock Fund Advsrs has invested 0% in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Vanguard Incorporated owns 121,156 shares or 0% of their US portfolio. Morgan Stanley reported 4,080 shares.